catalent inc. - CTLT

CTLT

Close Chg Chg %
58.98 0.68 1.15%

Closed Market

59.66

+0.68 (1.15%)

Volume: 1.19M

Last Updated:

Nov 21, 2024, 3:59 PM EDT

Company Overview: catalent inc. - CTLT

CTLT Key Data

Open

$58.92

Day Range

58.92 - 59.84

52 Week Range

36.74 - 61.18

Market Cap

$10.71B

Shares Outstanding

181.51M

Public Float

179.82M

Beta

1.16

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.27

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.85M

 

CTLT Performance

1 Week
 
-0.17%
 
1 Month
 
-0.15%
 
3 Months
 
-0.74%
 
1 Year
 
47.54%
 
5 Years
 
13.37%
 

CTLT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About catalent inc. - CTLT

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

CTLT At a Glance

Catalent, Inc.
14 Schoolhouse Road
Somerset, New Jersey 08873
Phone 1-732-537-6200 Revenue 4.38B
Industry Pharmaceuticals: Major Net Income -1,043,000,000.00
Sector Health Technology 2024 Sales Growth 2.768%
Fiscal Year-end 06 / 2025 Employees 16,900
View SEC Filings

CTLT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.323
Price to Book Ratio 2.824
Price to Cash Flow Ratio 37.976
Enterprise Value to EBITDA 23.465
Enterprise Value to Sales 3.396
Total Debt to Enterprise Value 0.335

CTLT Efficiency

Revenue/Employee 259,230.769
Income Per Employee -61,715.976
Receivables Turnover 2.798
Total Asset Turnover 0.427

CTLT Liquidity

Current Ratio 2.519
Quick Ratio 1.962
Cash Ratio 0.28

CTLT Profitability

Gross Margin 21.753
Operating Margin 3.31
Pretax Margin -23.442
Net Margin -23.807
Return on Assets -10.161
Return on Equity -25.393
Return on Total Capital -12.139
Return on Invested Capital -11.913

CTLT Capital Structure

Total Debt to Total Equity 138.402
Total Debt to Total Capital 58.054
Total Debt to Total Assets 51.143
Long-Term Debt to Equity 136.709
Long-Term Debt to Total Capital 57.344
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Catalent Inc. - CTLT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
4.00B 4.83B 4.26B 4.38B
Sales Growth
+29.21% +20.76% -11.70% +2.77%
Cost of Goods Sold (COGS) incl D&A
2.65B 3.19B 3.22B 3.43B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
289.00M 378.00M 422.00M 489.00M
Depreciation
196.00M 255.00M 286.00M 354.00M
Amortization of Intangibles
93.00M 123.00M 136.00M 135.00M
COGS Growth
+29.09% +20.48% +1.10% +6.36%
Gross Income
1.35B 1.64B 1.04B 953.00M
Gross Income Growth
+29.44% +21.30% -36.59% -8.37%
Gross Profit Margin
+33.82% +33.97% +24.40% +21.75%
2021 2022 2023 2024 5-year trend
SG&A Expense
679.00M 844.00M 731.00M 796.00M
Research & Development
21.00M 23.00M 18.00M 17.00M
Other SG&A
658.00M 821.00M 713.00M 779.00M
SGA Growth
+6.76% +24.30% -13.39% +8.89%
Other Operating Expense
- - 66.00M 12.00M
-
Unusual Expense
37.00M 43.00M 406.00M 894.00M
EBIT after Unusual Expense
636.00M 753.00M (163.00M) (749.00M)
Non Operating Income/Expense
189.00M (25.00M) 7.00M (24.00M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
110.00M 123.00M 186.00M 254.00M
Interest Expense Growth
-12.77% +11.82% +51.22% +36.56%
Gross Interest Expense
110.00M 123.00M 186.00M 264.00M
Interest Capitalized
- - - 10.00M
-
Pretax Income
715.00M 605.00M (342.00M) (1.03B)
Pretax Income Growth
+174.58% -15.38% -156.53% -200.29%
Pretax Margin
+17.88% +12.53% -8.02% -23.44%
Income Tax
130.00M 86.00M (86.00M) 16.00M
Income Tax - Current - Domestic
28.00M 7.00M (2.00M) (5.00M)
Income Tax - Current - Foreign
38.00M 66.00M 43.00M 48.00M
Income Tax - Deferred - Domestic
69.00M 6.00M (103.00M) (26.00M)
Income Tax - Deferred - Foreign
(5.00M) 7.00M (24.00M) (1.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - (56.00M) (16.00M)
-
Consolidated Net Income
529.00M 503.00M (256.00M) (1.04B)
Minority Interest Expense
- - - -
-
Net Income
529.00M 503.00M (256.00M) (1.04B)
Net Income Growth
+205.78% -4.91% -150.89% -307.42%
Net Margin Growth
+13.23% +10.42% -6.01% -23.81%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
529.00M 503.00M (256.00M) (1.04B)
Preferred Dividends
- - - -
-
Net Income Available to Common
529.00M 503.00M (256.00M) (1.04B)
EPS (Basic)
3.1488 2.858 -1.4144 -5.7624
EPS (Basic) Growth
+172.65% -9.24% -149.49% -307.41%
Basic Shares Outstanding
168.00M 176.00M 181.00M 181.00M
EPS (Diluted)
3.1118 2.8258 -1.4144 -5.7624
EPS (Diluted) Growth
+173.97% -9.19% -150.05% -307.41%
Diluted Shares Outstanding
170.00M 178.00M 181.00M 181.00M
EBITDA
962.00M 1.17B 665.00M 634.00M
EBITDA Growth
+45.27% +22.04% -43.36% -4.66%
EBITDA Margin
+24.06% +24.32% +15.60% +14.47%

Snapshot

Average Recommendation HOLD Average Target Price 63.486
Number of Ratings 11 Current Quarters Estimate 0.142
FY Report Date 12 / 2024 Current Year's Estimate 1.105
Last Quarter’s Earnings -0.13 Median PE on CY Estimate N/A
Year Ago Earnings 0.25 Next Fiscal Year Estimate 1.701
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 10 8
Mean Estimate 0.14 0.28 1.11 1.70
High Estimates 0.25 0.38 1.57 2.15
Low Estimate 0.02 0.19 0.84 1.34
Coefficient of Variance 66.72 24.84 20.65 18.94

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 1
HOLD 10 8 9
UNDERWEIGHT 1 1 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Catalent Inc. - CTLT

Date Name Shares Transaction Value
Sep 27, 2024 David Mcerlane Group President, Biologics 36,304 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $59.97 per share 2,177,150.88
Jul 11, 2024 Matti Masanovich SVP, Chief Financial Officer 33,871 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $56.74 per share 1,921,840.54
Jun 6, 2024 Ricky Hopson Pres. BioProduct Delivery, CoS 20,617 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.26 per share 1,118,678.42
Mar 20, 2024 Scott Gunther SVP, Quality & Reg. Affairs 29,506 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $56.2 per share 1,658,237.20

Catalent Inc. in the News